Unbiased Proteomics to
Accelerate Oncology Pipelines
Yatiri Bio, Inc. is a B2B precision-medicine biotech offering unbiased global mass-spectrometry proteomics, patient-derived cell models (ProteoModels), and CLIA/CAP biomarker development to help biopharmaceutical companies identify responsive patient subsets, discover companion diagnostics, and reduce clinical failure rates in oncology.
> Loading patient cell model cell_aml_venetoclax_2026
> ProteoModels matched: Target phosphorylation profile detected.
Oncology drug candidates show the lowest clinical success rate (only 3.4% approved) of all drug classes (Wong et al., 2019). We use high-throughput proteomics to isolate responsive subsets early.
Unlike targeted panels that miss novel signaling mechanisms, our unbiased global mass-spectrometry maps the complete proteome, providing deep translational data for target identification.
Through the acquisition of NGeneBioAI, Inc. in August 2025, we integrate certified laboratory infrastructure to translate research signatures directly into clinical assays.
Our Sellable B2B Services Catalog
Providing end-to-end biological characterization, computational modeling, and regulatory assay development for oncology pipeline translation.
Discovery Proteomics
Unbiased, large-scale mass spectrometry measuring 8,000+ proteins per sample to define complex biomarker profiles across cell lines, organoids, tissues, and clinical biofluids.
PTM & Phosphoproteomics
Quantify post-translational modifications (PTMs), specifically phosphorylation states, to map hyperactive kinase networks, discover drug targets, and identify drug resistance escape paths.
ProteoModels Efficacy
Screen candidate therapeutics across patient-derived cell models paired with full baseline proteomic characterization, identifying mechanisms and testing drug sensitivity.
AI & Bioinformatics
Extract biological signal from high-dimensional datasets using machine learning algorithms, pathway enrichment tools, and proprietary visualization tools (ProteoBrowser™).
CLIA Biomarker & Companion Dx
Transition research signatures into clinically actionable, validated assay tests inside our regulatory-certified laboratory infrastructure to qualify patient cohorts for clinical runs.
Translational Consulting & Partnerships
Design clinical trials with predictive patient selection protocols and leverage ex-vivo biomarker correlation under custom B2B biopharma consulting contracts.
How We Optimize Oncology Drug Pipelines
Our structured workflow matches unbiased proteomics discovery to validated clinical assays.
Sample Extraction
Biopharma cohorts provide cell lines, organoids, tissues, or biofluid samples. Our lab prepares clinical inputs for processing.
High-Throughput Mass Spec
Unbiased, deep global proteomics runs quantify 8,000+ total proteins and phosphorylation modifications per sample.
In Silico Analysis
ProteoBrowser™ algorithmic models correlate protein networks to ex-vivo drug sensitivity, isolating patient subset targets.
CLIA/CAP Assay Testing
Signatures are validated inside NGeneBioAI CLIA-certified labs to select patient targets for live clinical trials.